Array BioPharma

Array BioPharma, Celgene announce collaboration

Wednesday, July 31, 2013 11:49 AM

Array BioPharma will collaborate with New Jersey-based biopharmaceutical company Celgene for an Array-invented preclinical development program targeting a novel inflammation pathway.  Array will receive an up-front payment of $11 million and Celgene will have an exclusive option to license multiple clinical development candidates. Array is entitled to receive potential milestone payments of up to $376 million based upon achieving certain development, regulatory and sales objectives. Array is also entitled to receive royalties on net sales of all drugs and will retain all rights to the program if Celgene does not exercise its option.

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

Array BioPharma initiates MILO study

Tuesday, July 9, 2013 12:36 PM

Array BioPharma said a $5 million milestone was achieved after the start of Array's phase III trial in patients with low-grade serous ovarian cancer (LGSOC).

More... »

Array BioPharma names Michael Needle as chief medical officer

Friday, March 22, 2013 11:14 AM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs to treat cancer, has appointed Michael N. Needle, M.D., as its chief medical officer. 

More... »

Orwin joins Array BioPharma’s board of directors

Friday, November 9, 2012 02:29 PM

Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs for the treatment of cancer, has appointed John A. Orwin, CEO of Affymax, to Array's board of directors as part of its continued evolution toward late-stage development and commercialization.

More... »

Array BioPharma’s ARRY-797 meets primary endpoint in osteoarthritis study

Friday, August 3, 2012 12:41 PM

Boulder, Colo.-based Array BioPharma’s phase II study of ARRY-797 met its primary endpoint osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

More... »

Array signs $685 million agreement with Genentech

Tuesday, August 9, 2011 12:08 PM

Array BioPharma has signed an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule checkpoint kinase 1 (ChK-1) program. The programs include Genentech's compound GDC-0425 (RG7602), currently in phase I, and Array's compound ARRY-575, which is being prepared for an investigational new drug application to initiate a phase I trial in cancer patients.

More... »

Array BioPharma restructures to focus on clinical programs

Tuesday, June 14, 2011 02:25 PM

Boulder, Colo.-based Array BioPharma is restructuring to extend its financial resources and to focus on the development of its key clinical programs.

More... »